Free press releases distribution network?

Agency / Source: Foamix Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Foamix Granted Comprehensive US Patent for PerFoam® - Ideal Foam Treatment for Head Lice and Scabies - Foamix Ltd, a clinical-stage specialty pharmaceutical company, that is developing proprietary dermatological and gynecologic topical foam products, today announced that the company has been granted a new patent from United States Patent Office
Foamix Granted Comprehensive US Patent for PerFoam® - Ideal Foam Treatment for Head Lice and Scabies

 

PRZOOM - /newswire/ - Rehovot, Israel, 2012/03/13 - Foamix Ltd, a clinical-stage specialty pharmaceutical company, that is developing proprietary dermatological and gynecologic topical foam products, today announced that the company has been granted a new patent from United States Patent Office.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

US Patent No. 8,119, 150, entitled “Non-flammable insecticide composition and uses thereof” relates to Foamix’s novel safe and effective insecticide compositions, suitable for treating insect infestations.

Foamix’s Permethrin 1% foam (“PerFoam® One”) was developed for the treatment of head lice. It was tested clinically in 56 children, infested with head lice; and demonstrated a 96% efficacy rate, with no side effects. From the usability point of view, PerFoam® One is superior. It is easy to apply, allows precise application without spreading on clothes or other parts of the body, and no protection of the eyes is required.

PerFoam® Five, Foamix’s Permethrin 5% foam is directed for the treatment of scabies. While anti-scabies creams require extensive rubbing throughout the whole body surface, foam makes treatment easy. The Foamix foam spreads readily on large skin areas and absorbs quickly.
This invention further relates to a variety of insecticide compounds that can be incorporated in foam to create best-in-class medications for parasite therapy.
"The grant of our PerFoam® patent in the US broadens our intellectual property portfolio," said Dr. Dov Tamarkin, CEO of Foamix. “We will now be able to imply our superior foam platforms and technologies into a patent protected product for treating head lice and scabies."

About Head Lice
The Centers for Disease Control and Prevention (CDC) (2010) reports an estimated 6 million to 12 million infestations occur each year in the United States among children 3 to 11 years of age. Girls are at greater risk because they have more frequent head-to-head contact. Head lice affect people across the socioeconomic spectrum.

About PerFoam® One
Foamix’s PerFoam® One, comprised of 1% Permethrin and two proprietary enhancers, is an alcohol-free, non-irritating, drip-free foam for the treatment of head lice. A clinical study entitled “An open study to assess the efficacy, safety and usability of a 1% Permethrin Foam, in the treatment of head lice (pediculosis capitis) in pediatric patients” was conducted at the Laniado Medical Center, Israel. Fifty-six children, aged 3-16, infested with head lice, were treated with PerFoam® One. The foam was applied to the hair for 10 minutes and then washed. Treatment was repeated 10 days later. PerFoam® One proved effective in killing the lice on the first application in 54 of the 56 children (96.4%). Furthermore, in 60% of the children, lice eggs were completely eradicated after the first application. The product was easily applied and caused no discomfort to the treated children. There was no evidence of eye or skin irritation.

About Scabies
Scabies is one of the three most common skin disorders in children.1 The mites are distributed around the world and equally infect all ages, races, and socioeconomic classes in different climates. Over 300 million people are affected by scabies worldwide, with millions of infections in the U.S. alone.2 People of all ages, genders, races, and social classes get scabies; and they easily spread within families, to sexual partners, and among people living in crowded conditions.

A number of medications is effective in treating scabies; however treatment must often involve the entire household or community to prevent re-infection.

Permethrin is the most effective treatment for scabies, and the treatment of choice. It is applied from the neck down usually before bedtime and left on for about 8 to 14 hours. Foam is an ideal carrier for scabies medications, as it spreads easily on large skin areas and absorbs quickly.
1 Pediatr Clin North Am. 2009 Dec;56(6):1421-40.
2 Lancet. 2000;355:819–826.

About PerFoam® Five
Foamix’s PerFoam® Five is an emollient formulation of Permethrin, ideal for the treatment of scabies and severe cased of pediculosis. It spreads easily on large skin areas and absorbs immediately upon application, and thus is expected to provide significant advantage to patients, in comparison to the traditional creams which require extensive rubbing in order to attain adequate spreading and absorption.

About Foamix
Foamix Ltd (foamix.co.il) is a clinical-stage, privately held specialty pharmaceutical company, focused on the development of proprietary topical foams and OilGel™ products for dermatology, gynecology, wounds and burn applications, as well as ophthalmic disorders. Foamix collaborates with leading pharmaceutical companies in the creation of advanced products with improved convenience, higher compliance and better efficacy, which are backed by an extensive patent portfolio.

The Company’s development capabilities range from initial development of the formulations and analytical methods to scale-up, GMP manufacturing, preclinical and clinical studies.

Foamix has a strong in-house pipeline. The Company’s lead product, Topical Minocycline, is currently in Phase II clinical studies.
To date, Foamix has 13 issued patents in the United States, covering its foam and OilGel™ technology platforms. Additionally, the company has more than 140 patents and patent applications worldwide, of which about 60 applications are filed in the U.S.

Contacts:
Dorit Hayon, Business Development Manager, Foamix Ltd, dorit[.]foamix.co.il
Dov Tamarkin, CEO, Foamix Ltd, dov[.]foamix.co.il.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Foamix Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Foamix Granted Comprehensive US Patent for PerFoam® - Ideal Foam Treatment for Head Lice and Scabies

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Dorit Hayon - Foamix.co.il 
+972 8 9316233
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Foamix Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Foamix Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris
MDxHealth Signs Agreement with Lab21 to Make SelectMDx Liquid Biopsy Test Available in the United Kingdom
Greenphire Drives Global Site Adoption of Clinical Trial Payment Solutions
SelectMDx Chosen by Michigan Medicine as Pre-biopsy Diagnostic Tool in Groundbreaking US Prostate Cancer Risk Clinic
BTG Announces CE Mark Certification for DC Bead LUMI™ - The First Commercially Available Radiopaque Drug-Eluting Bead
Sartorius to Acquire Real-time Live-cell Analysis Pioneer and Leader Essen BioScience
Pyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BTG Receives U.S. FDA 510(k) Clearance for EKOS® Control Unit 4.0
MDxHealth Announces Agreement with Istituto Diagnostico Varelli for Distribution of SelectMDx Throughout Central-South Italy
BD Veritor™ System Meets FDA’s New Performance Requirements for Rapid Influenza Antigen Detection Tests

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today